NCT04722900 PREG - Offspring: Investigation of Children From Mothers With and Without Gestational Diabetes
| NCT ID | NCT04722900 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Tuebingen |
| Condition | Offspring Exposed to GDM and Control |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2021-01-15 |
| Primary Completion | 2036-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2021-01-15 with a primary completion date of 2036-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gestational diabetes is the most common complication during pregrancy. With a screening between week 24 and 28 of gestation women with gestational diabetes can be identified and treated. Treatment comprises modification of diet and in some cases taking medication. This treatment lowers undesirable events like macrosomia or premature birth. However, unitl gestational diabetes is diagnosed the fetus is exposed to increased intrauterine glucose levels. The long-term effects of a well-managed gestational diabetes on the development of the offspring is still not well understood. Therefore, the PREG - Offspring study investigates several aspects of development in children from healthy and gestational diabetes mothers until adulthood.
Eligibility Criteria
Inclusion Criteria: * signed informed consent provided by child and parent * documented oral glucose tolerance test of the mother during pregnancy * adequate management of gestational diabetes until birth Exclusion Criteria: * severe malformation that makes an examination impossible * existent of coagulation disorder with increased risk of bleeding after blood sampling
Contact & Investigator
Andreas Fritsche
PRINCIPAL INVESTIGATOR
University Hospital Tübingen
Frequently Asked Questions
Who can join the NCT04722900 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 17 Years, studying Offspring Exposed to GDM and Control. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04722900 currently recruiting?
Yes, NCT04722900 is actively recruiting participants. Contact the research team at louise.fritsche@med.uni-tuebingen.de for enrollment information.
Where is the NCT04722900 trial being conducted?
This trial is being conducted at Tübingen, Germany.
Who is sponsoring the NCT04722900 clinical trial?
NCT04722900 is sponsored by University Hospital Tuebingen. The principal investigator is Andreas Fritsche at University Hospital Tübingen. The trial plans to enroll 100 participants.